Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
for Breast Cancer
7 locations incl. San Francisco
Sponsor: Massachusetts General Hospital
Sex: Female·Age: 18+
Code: NCT03990896·Phase 2·Recruiting